Nomic® and PICI Launch Large-Scale Protein Profiling in RADIOHEAD Immunotherapy Study

Nomic Bio Inc., a leader in proteomics with advanced technology for multiplexed protein quantification, and the Parker Institute for Cancer Immunotherapy (PICI), a notable consortium of immuno-oncology experts, have announced a research partnership. This collaboration aims to measure circulating protein biomarkers linked to patient responses to immunotherapy across various cancers.

As part of this endeavor, Nomic will analyze blood samples from PICI’s RADIOHEAD cohort, a comprehensive study including 1,070 patients undergoing standard immune checkpoint inhibitor (ICI) treatments at 52 community hospitals across the United States. Utilizing Nomic’s nELISA platform, the research will achieve parallel quantification of hundreds of proteins involved in cancer and immune responses. The objective is to evaluate inflammatory and cancer-related protein levels and investigate their correlations with therapy responses, patient survival rates, and the risk of immune-related adverse events.

Tarak Mody, PICI’s chief business officer, emphasized the goal of the research, stating, "By analyzing the soluble signaling molecules in our longitudinal patient samples, we hope to unravel the communication pathways among immune cells in response to diseases and treatments." He further noted that the data from this collaboration, combined with other omics information in the RADIOHEAD program, will advance understanding of treatment resistance and accelerate precision medicine innovations to enhance patient care.

The project leverages Nomic's breakthrough nELISA platform, which is renowned for its specificity and ability to provide absolute quantification of numerous key protein targets. These technological advancements, along with high throughput capacity, have positioned Nomic as a leading solution provider in drug discovery.

Milad Dagher, Nomic’s CEO and Co-Founder, expressed enthusiasm about the collaboration with PICI. "We are thrilled to partner with PICI to better understand how cancer patients respond to immunotherapy, which is becoming increasingly common for various cancer types," Dagher said. He highlighted Nomic’s mission to empower scientists with critical data to improve patient outcomes, viewing this partnership as an opportunity to apply their technology to enhance decision-making in immunotherapy treatments.

Nomic and PICI plan to start publishing the data generated by this study in early 2025.

Nomic is dedicated to making protein profiling widely accessible, with its nELISA™ technology at the core. This proprietary platform allows for extensive multiplexing, comprehensive quantification, and cost-efficiency. Nomic has developed a robust solution for inflammation research, enabling high-throughput quantification of numerous secreted proteins. The company is rapidly expanding its capabilities across the proteome, unlocking new possibilities for diverse applications and disease research.

PICI, established through significant funding from entrepreneur Sean Parker, revolutionizes cancer research by uniting top immunotherapy researchers and cancer centers. The institute’s mission is to accelerate the development of groundbreaking immunotherapies to transform all cancers into curable conditions. The PICI Network includes prominent research institutions such as Stanford Medicine, UCLA, UCSF, University of Pennsylvania, Dana-Farber Cancer Institute, and more. PICI supports researchers at other renowned institutions, fostering partnerships with academic, industry, and nonprofit entities to pursue bold research initiatives.